In connection with two inter partes review (IPRs) proceedings, the U.S. Patent Trial and Appeal Board (PTAB) invalidated 25 claims from two patents owned by competitor Luitpold Pharmaceuticals, Inc. relating to parenteral iron therapy, and Luitpold appealed the decisions in both IPRs. The Federal Circuit summarily affirmed those decisions under Federal Circuit Rule 36 today.
The Baker Botts team was led by Paul Ragusa, who argued the appeals before the Federal Circuit. The team included partners Jennifer Tempesta, Steve Lendaris, Lisa Kole (retired) and associates Carolyn Pirraglia and Amy Song.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 725 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy and technology sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.